Samsung Biologics Launches $2.2 Billion Rights Offering for PolyPeptide Deal
Samsung Biologics is raising approximately 3 trillion won through a rights issue to finance its planned acquisition of Danish peptide maker PolyPeptide Group. The capital injection supports the company’s strategic expansion into next-generation biomanufacturing.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (43/100)Sources
Samsung Biologics to Raise $2.2 Billion to Fund PolyPeptide Deal
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
By Youkyung Lee and Denny Thomas
Read full article →Samsung Biologics to raise W3tr in rights issue for peptide maker deal
Samsung Biologics is planning to raise over 3 trillion won ($2.2 billion) through a share offering to fund its acquisition of a peptide manufacturer and a new production campus, as competition among global drugmakers intensifies. In a regulatory filing Friday, Samsung Biologics said its board approved the offering, issuing 2.27 million new shares at 1,322,000 won apiece, a 15 percent discount that will expand its share count by 4.9 percent. Of the proceeds, 2.71 trillion won will fund the acquis
By The Korea Herald
Read full article →Samsung Biologics to raise 3 tln won via rights offering
SEOUL, Aug. 28 (Yonhap) -- Samsung Biologics announced Friday it would raise 3 t...
By Kang Jae-eun
Read full article →Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion - Taiwan News
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion Taiwan News
Read full article →
